Stent technology maker InspireMD (OTC:NSPR) gained a few points on Wall Street today on news that the FDA gave the company a conditional green light to proceed with a clinical trial of its MGuard Embolic Protection Stent.
The Tel-Aviv-based medical device company said the MGuard device is wrapped with its MicroNet mesh to prevent embolisms – blood clots – from occurring during and after the placement of a carotid stent.
The Sunnyvale, Calif.-based medical device company said it will use the proceeds from the offering of debt due Feb. 1, 2018, to shore up its balance sheet.
Intarcia Therapeutics said it’s reeled in financing worth a total of $210 million to further its drug-device combination treatment for Type II diabetes.
The Hayward, Calif.-based company, which is moving its headquarters to Boston, said the cash will also help facilitate the move.
The Sunnyvale, Calif.-based radiosurgery device maker reported losses of $14.9 million, or 21¢ per share, on sales of $101.8 million during the 3 months ended March 31.